T-Cypher Bio Ltd

At T-Cypher, we develop T cell engagers against novel disease-specific targets to improve the lives of patients with cancer and autoimmune diseases. We focus on radical discoveries in science and technology to innovate immune system engaging medicines that expand treatment possibilities for patients. We are driven to increase the likelihood of curative outcomes.

Our immune system is our defense against diseases but is not created equal in all of us. Some of us develop diseases that others are well protected against. Diversity in our immune responses reflects differences in our genetic codes and other factors, resulting in alterations in our cells and their communication.

At T-Cypher we decode how changes in cellular communication relates to disease, and use this knowledge to build new medicines that correct the underlying causes of disease.

We have identified new disease-specific targets that enable us to restore optimal immune system functionality through the medicines we develop. We have a diverse pipeline of immune engagers against novel targets across a range of solid tumours as well as in selected autoimmune diseases. First IND will be in 2027. 

Our approach to making new medicines is fuelled by a set of proprietary platform technologies that combine wet-lab and computational methodologies.

The integration of these platforms results in the generation of massive datasets and data architecture that enables us to study hidden connections in the highly complex biology related to immune system surveillance of our tissues.

Ultimately, we identify key connections related to disease and utilise the new insights to build transformative medicines.

• Platform Technology
• Autoimmune diseases
• Oncology